Enhanced Abuse-Deterrent Pharmaceutical Compositions with pH-Dependent Solubility Features

The inventive concept relates to improved pharmaceutical compositions that incorporate pH-dependent solubility features and buffering ingredients to self-regulate the release of active pharmaceutical ingredients, thereby reducing the potential for abuse and overdose.

The original patent disclosed methods and compositions for self-regulated release of active pharmaceutical ingredients, but had limitations in terms of peak plasma concentration and release timing. The new inventive concept addresses these limitations by incorporating pH-dependent solubility features and buffering ingredients to modify the gastric environment and retard release of the active pharmaceutical ingredient when ingested in excess.

The enhanced abuse-deterrent pharmaceutical compositions comprise a pH-dependent solubility feature, which slows or blocks the release of the active pharmaceutical ingredient in response to excessive doses. The compositions also include a buffering ingredient that modifies the gastric environment to further regulate the release of the active pharmaceutical ingredient. This results in a safer and more efficient delivery of the active pharmaceutical ingredient, reducing the potential for abuse and overdose.

The new inventive concept introduces the use of pH-dependent solubility features and buffering ingredients to self-regulate the release of active pharmaceutical ingredients, providing a significant improvement over the original patent. The combination of these features enables a more controlled and safer delivery of the active pharmaceutical ingredient, reducing the potential for abuse and overdose.

Alternative embodiments of the inventive concept could include the use of different pH-dependent solubility features, such as polymers or lipids, or the incorporation of additional ingredients to further modify the gastric environment. Variations of the inventive concept could also include the use of different buffering ingredients or the optimization of the composition for specific active pharmaceutical ingredients.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the development of abuse-deterrent formulations for opioids and other drugs with narrow therapeutic indices. The market for such formulations is substantial, driven by the need to address the growing problem of drug abuse and overdose.